Mimetica is a Brisbane-based biotechnology company which has developed a class of small molecule scaffolds that mimic reverse-turn motifs of peptides. These scaffolds have been used to create small molecule mimics of several important peptides and proteins known to be involved in the pathogenesis of disease. Mimetica is currently focusing its initial drug development activities on dermatological applications.
Mimetica Frequently Asked Questions (FAQ)
What is Mimetica's latest funding round?
Mimetica's latest funding round is Other Investors.
Who are the investors of Mimetica?
Investors of Mimetica include Starfish Ventures.
Who are Mimetica's competitors?
Competitors of Mimetica include Array Biopharma, Integrated DNA Technologies, Threshold Pharmaceuticals, Calibrant Biosystems, Bikam Pharmaceuticals and 11 more.
Compare Mimetica to Competitors
Trellis Bioscience provides healthcare products and services. The Company develops treatments for infectious diseases and oncology indications such as therapeutic antibody treatments. The company was founded in 1998 and is based in Redwood City, California.
Norgen Biotek Corp. is a biotechnology company focusing principally on advancing sample preparation products for nucleic acid (DNA & RNA) and protein purification, clean-up and concentration. Norgen has one platform technology with many applications based on a resin that can be applied in the purification of DNA, RNA and proteins. The uniqueness and novelty of this technology has been recognized by the National Research Council through awarding Norgen the prestigious "Innovation Leader Award for 2003". The company holds more than a dozen issued patents and several others are pending. Norgen currently manufactures over 40 products that are used by researchers working in genomics and proteomics in academia, pharma/biotech companies, and government institutions.
Amrita Therapeutics develops drugs that combat public health threats of the 21st century with fewer side-effects and at an cost. Amrita Therapeutics therapies and cures will treat cervical cancer, CNS disorders, HIV/AIDS, malaria and/or tuberculosis by designing the products of bacteria to defend the human body against more than one disease simultaneously, utilizing or interfering in multiple pathways or mechanisms.
Spider Biotech is a young and dynamic biotechnology company founded in 2005 with the aim of developing synthetic peptide therapeutics. nnAntimicrobial host-defense peptides have been recognized as an important part of innate immunity found throughout the evolutionary tree that defend against invading bacteria, viruses, and fungi through membrane or metabolic disruption. Inspired by natural antimicrobial peptides, Spider Biotech is developing a library of bioactive peptides and lipopeptides active against bacterial and viral infections. nSpiderBiotech's business strategy is to remain focused on the discovery and early-stage development of drug candidates and seek to establish partnerships with pharmaceutical companies for late-stage development and commercialization of its products. nnThe firm aims to become leader in developing peptide-based antiinfectives to address the urgent and global problem posed by resistance to conventional treatments. The Company is headquartered at the Bioindustry Park del Canavese (Turin, Italy).
CellXplore is a new, biotechnology company engaged in the development of biomarker-based in vitro diagnostic assays for cancer, initially focusing on breast cancer. Although mammography is an effective screening test for early detection, there is a need for a simple, reliable and sensitive biomarker-based in vitro assay that can be used to stage and characterize breast cancer.nThe company was formed to commercialize groundbreaking discoveries demonstrating up-regulation of the ubiquitin-proteasome pathway in cancerous breast tissue, providing the capability for the noninvasive detection of breast cancer and the ability to monitor the efficacy of chemotherapeutic interventions.nCellXplore's platform technology is not restricted to breast cancer in vitro diagnostics alone, nor is it restricted to cancer diagnostics alone. Beyond cancer, CellXplore is already investigating whether similar blood sample biomarkers can be identified for the early diagnosis of several major debilitating diseases such as muscle wasting, Alzheimer's disease, Parkinson's disease and inflammatory diseases.
Elevation Biotech specialises in the design and discovery of small peptide and peptidomimetic HIV attachment inhibitors. The company have developed biochemical and virological in vitro assays that screen specifically for the ability of compounds to block or interfere with viral attachment to the cell surface receptor CD4. The company's lead compound, is a short 7 amino acid peptide that binds to HIV envelope protein gp120 thereby preventing attachment of virus to the CD4 molecule.